You are here
VANGUARD THERAPEUTICS, INC.
UEI: W27EZJ6JUGH3
# of Employees: 4
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Improved Oral P-selectin Blocker for Prophylactic Sickle Cell Disease Therapy
Amount: $1,675,225.00Abstract Sickle cell disease SCD is a poorly treated inherited debilitating condition for which Vanguard Therapeutics Inc is developing a promising new long term oral therapy A dire need exists ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
Improved Oral P selectin Blocker for Prophylactic Sickle Cell Disease Therapy
Amount: $1,992,324.00Abstract Sickle cell disease SCD is a poorly treated inherited debilitating condition for which Vanguard Therapeutics Inc is developing a promising new long term oral therapy A dire need exists ...
SBIRPhase II2016Department of Health and Human Services National Institutes of Health -
Improved Oral P-selectin Blocker for Prophylactic Sickle Cell Disease Therapy
Amount: $226,033.00DESCRIPTION (provided by applicant): Sickle cell disease (SCD) is a poorly treated debilitating condition for which we are developing a promising, new oral prophylactic therapy. A dir ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
Reliable Assays for Pentosan Polysulfate Sodium
Amount: $335,702.00DESCRIPTION provided by applicant Sickle cell disease SCD remains a poorly treated disease Based on evidence that endothelial P selectin is central to the abnormal microvascular blood flow in SC ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health
